Clinical characteristics of 34 patients with GPA-related SGS.
| Variable | No. Patients |
|---|---|
| Female | 23 |
| Male | 11 |
| Age, yrs | 18–78 |
| Median age, yrs | 46 |
| SGS diagnosis | |
| SGS as the only symptom of GPA | 2 |
| SGS diagnosed in clinical remission of GPA | 15 |
| SGS + activity of GPA in other organs | 17 |
| BVAS, organ involvement | 34 |
| 0 | 15 |
| 1: sinus | 9 |
| 2: ENT, sinus | 1 |
| 3: sinus, kidney | 3 |
| 4: sinus, ocular, kidney | 4 |
| 5: sinus, skin, lung | 1 |
| 9: sinus, ocular, lung, kidney | 1 |
| Trachea biopsy | 26/34 |
| GPA confirmation | 16/26 |
| Noncharacteristic pattern | 10/26 |
| ANCA present | 24/34 |
| Clinical symptoms | |
| Dyspnea | 34 |
| Cough | 11/34 |
| Hoarseness | 10/34 |
| Pulmonary function tests | |
| Desaturation in walking test | 4/26 |
| Hypoxemia, < 70 mmHg | 7/34 |
| Obstruction of spirometry, FEV1/FVC < 0.7 | 17/26 |
| Treatment type | |
| Only IDIT | 13 |
| IDIT + IST, activity in other organs | 17 |
| IDIT + IST, persistent symptoms of SGS | 4 |
| Overall | 34 |
GPA: granulomatosis with polyangiitis; SGS: subglottic stenosis; BVAS: Birmingham Vasculitis Activity Score; ENT: ear, nose, throat; ANCA: antineutrophil cytoplasmic antibodies; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; IDIT: intratracheal dilation-injection technique; IST: immunosuppressive therapy.